MedTrace Logo

Study of Aripiprazole to Treat Children and Adolescents With Autism

NCT00619190 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-03-26

Study results available
· View outcomes & findings →

Summary

The purpose of this open label study in children and adolescents is to examine the acute and long-term effects of aripiprazole on problem behaviors associated with autism spectrum disorders and development in areas which appear to be affected by autism spectrum disorders.

Conditions

Interventions

DRUG

aripiprazole

aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months

Sponsors & Collaborators

Principal Investigators

  • Linmarie Sikich, MD · University of North Carolina, Department of Psychiatry

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Months
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619190 on ClinicalTrials.gov